Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,641.89% | -173.90% | -46.07% | 370.55% | -76.22% |
| Total Depreciation and Amortization | 39.69% | 66.27% | 67.38% | 33.32% | 9.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 241.73% | 211.33% | 854.99% | -4,042.75% | 5,624.47% |
| Change in Net Operating Assets | 62.80% | 17.83% | 79.01% | 518.63% | -76.75% |
| Cash from Operations | 55.47% | 717.55% | 216.04% | -30.61% | -320.66% |
| Capital Expenditure | 100.00% | -- | -- | 24.73% | -57,900.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | 24.73% | -57,900.00% |
| Total Debt Issued | -- | -- | -- | 100.00% | -- |
| Total Debt Repaid | -413.56% | -78.66% | -308.64% | 96.76% | 51.42% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -413.56% | -78.66% | -104.42% | 97.11% | 51.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 55.63% | 377.73% | 4.72% | 112.86% | -338.45% |